If there are more failures such as GILD in HepC then those companies may think they are better off combining with Bavi and increase their chances rather then not add it and being whistled back.
I think we discussed, some time ago already, on this board that Bavi's future in HepC was very probably going to be something to combine with something else.
That's where those safety profiles are so important for. Nobody would add something to their cocktail that makes their overall safety bad. That's Bavi's strong point: It works and adds to the result, it is save and it has a certain latency that probably will influence the number of relapses or at least the time after which that happens.
Maybe Peregrine needs someone for "Bavi HepC Cocktails" that should open channels with all the Gileads and alikes and sell them the above advantages so they would sponsor clinical trails for a cocktail of their product + Bavi HepC.
Something tells me that is not what they do at Peregrine, I think they sit and wait until the phone rings and I think that is not the way to do it.